ALKS
Price
$29.83
Change
-$0.95 (-3.09%)
Updated
Jun 13 closing price
Capitalization
4.55B
39 days until earnings call
EOLS
Price
$9.93
Change
-$0.25 (-2.46%)
Updated
Jun 13 closing price
Capitalization
846.82M
46 days until earnings call
Interact to see
Advertisement

ALKS vs EOLS

Header iconALKS vs EOLS Comparison
Open Charts ALKS vs EOLSBanner chart's image
Alkermes
Price$29.83
Change-$0.95 (-3.09%)
Volume$2.21M
Capitalization4.55B
Evolus
Price$9.93
Change-$0.25 (-2.46%)
Volume$1.19M
Capitalization846.82M
ALKS vs EOLS Comparison Chart
Loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. EOLS commentary
Jun 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Hold and EOLS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 14, 2025
Stock price -- (ALKS: $29.83 vs. EOLS: $9.93)
Brand notoriety: ALKS and EOLS are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ALKS: 130% vs. EOLS: 110%
Market capitalization -- ALKS: $4.55B vs. EOLS: $846.82M
ALKS [@Pharmaceuticals: Other] is valued at $4.55B. EOLS’s [@Pharmaceuticals: Other] market capitalization is $846.82M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 2 FA rating(s) are green whileEOLS’s FA Score has 0 green FA rating(s).

  • ALKS’s FA Score: 2 green, 3 red.
  • EOLS’s FA Score: 0 green, 5 red.
According to our system of comparison, ALKS is a better buy in the long-term than EOLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 4 TA indicator(s) are bullish while EOLS’s TA Score has 4 bullish TA indicator(s).

  • ALKS’s TA Score: 4 bullish, 5 bearish.
  • EOLS’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, EOLS is a better buy in the short-term than ALKS.

Price Growth

ALKS (@Pharmaceuticals: Other) experienced а -5.93% price change this week, while EOLS (@Pharmaceuticals: Other) price change was -1.10% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.42%. For the same industry, the average monthly price growth was +14.50%, and the average quarterly price growth was +67.02%.

Reported Earning Dates

ALKS is expected to report earnings on Jul 23, 2025.

EOLS is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-0.42% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALKS($4.55B) has a higher market cap than EOLS($847M). ALKS YTD gains are higher at: 3.720 vs. EOLS (-10.054). ALKS has higher annual earnings (EBITDA): 519M vs. EOLS (-41.81M). ALKS has more cash in the bank: 773M vs. EOLS (62.8M). EOLS has less debt than ALKS: EOLS (127M) vs ALKS (372M). ALKS has higher revenues than EOLS: ALKS (1.66B) vs EOLS (202M).
ALKSEOLSALKS / EOLS
Capitalization4.55B847M537%
EBITDA519M-41.81M-1,241%
Gain YTD3.720-10.054-37%
P/E Ratio8.90N/A-
Revenue1.66B202M823%
Total Cash773M62.8M1,231%
Total Debt372M127M293%
FUNDAMENTALS RATINGS
ALKS vs EOLS: Fundamental Ratings
ALKS
EOLS
OUTLOOK RATING
1..100
7263
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
2860
SMR RATING
1..100
38100
PRICE GROWTH RATING
1..100
5663
P/E GROWTH RATING
1..100
9100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EOLS's Valuation (91) in the Pharmaceuticals Major industry is in the same range as ALKS (99) in the Biotechnology industry. This means that EOLS’s stock grew similarly to ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (28) in the Biotechnology industry is in the same range as EOLS (60) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew similarly to EOLS’s over the last 12 months.

ALKS's SMR Rating (38) in the Biotechnology industry is somewhat better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew somewhat faster than EOLS’s over the last 12 months.

ALKS's Price Growth Rating (56) in the Biotechnology industry is in the same range as EOLS (63) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew similarly to EOLS’s over the last 12 months.

ALKS's P/E Growth Rating (9) in the Biotechnology industry is significantly better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that ALKS’s stock grew significantly faster than EOLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSEOLS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
59%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 13 days ago
76%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FBSAX37.58N/A
N/A
Franklin Mutual U.S. Mid Cap Value Adv
SUHAX36.19N/A
N/A
DWS Health and Wellness A
MIGDX31.93N/A
N/A
MFS Massachusetts Inv Gr Stk C
FMCEX36.00N/A
N/A
Fidelity Advisor Stock Selec Mid Cp C
RUSRX10.51N/A
N/A
Lazard US Systematic Small Cap Eq R6

ALKS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALKS has been loosely correlated with VTRS. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ALKS jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
-3.09%
VTRS - ALKS
35%
Loosely correlated
-1.87%
ESPR - ALKS
34%
Loosely correlated
-2.50%
PRGO - ALKS
34%
Loosely correlated
-2.20%
DVAX - ALKS
33%
Loosely correlated
-1.25%
AMRX - ALKS
33%
Loosely correlated
-2.64%
More

EOLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EOLS has been loosely correlated with AMRX. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if EOLS jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EOLS
1D Price
Change %
EOLS100%
-2.46%
AMRX - EOLS
33%
Loosely correlated
-2.64%
ALKS - EOLS
31%
Poorly correlated
-3.09%
NBIX - EOLS
30%
Poorly correlated
-0.50%
AQST - EOLS
30%
Poorly correlated
+3.32%
PRGO - EOLS
28%
Poorly correlated
-2.20%
More